The University of Southampton
University of Southampton Institutional Repository

Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom

Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom
Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom
Aims and background: the ABC-02 trial has defined the standard therapy for patients with advanced biliary tract cancer (ABC); however, outcome in an unselected patient population in the UK has not been described. We aimed to investigate the outcome of a series of patients with ABC from two large UK cancer networks.

Methods and study design: we retrospectively reviewed all cases of ABC presenting to two UK cancer networks over a nine-year period. Overall survival (OS) and factors influencing OS were assessed.

Results: four hundred and two patients were available for analysis. The median OS was 6.2 months. On univariate analysis, age ≥70 years (P = 0.047), advanced disease stage (P <0.001), gall bladder primary (P = 0.033), poor performance status (P <0.001) and lack of chemotherapy (P <0.001) were associated with worse outcome. Survival was superior in the 36.4% of patients who received palliative chemotherapy (12.5 vs 4.3 months; P <0.001). On multivariate analysis of patients who had chemotherapy, those who did not receive fluoropyrimidine-based regimens (HR = 5.12; P = 0.022) or gemcitabine-based regimens (HR = 5.01; P = 0.021) had a higher mortality, whereas the effect of platinum-containing regimens was of borderline significance (HR = 2.23; P = 0.086). Sites, age, and multi-agent regimens were not significant.

Conclusions: this is one of the largest retrospective studies reporting outcome of palliative chemotherapy for ABC. It confirms the benefit of palliative chemotherapy in an unselected group of patients. Fluoropyrimidine-based regimens appear to be as effective as gemcitabine-based treatments.
0300-8916
219-224
Huggett, Matthew T.
0c41c557-9548-4020-bef1-07e132868aef
Passant, Helen
b934cc86-c9c2-470a-9168-7dbe72112d5a
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Pereira, Stephen P.
c9485183-9457-499a-87e4-abf8a5fd83fa
Bridgewater, John
a9612e28-f0c0-4792-8be5-e14b2cd07408
Mukherjee, Somnath
d9278fe6-ec80-45e0-b3ab-137e668787e8
Huggett, Matthew T.
0c41c557-9548-4020-bef1-07e132868aef
Passant, Helen
b934cc86-c9c2-470a-9168-7dbe72112d5a
Hurt, Chris
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Pereira, Stephen P.
c9485183-9457-499a-87e4-abf8a5fd83fa
Bridgewater, John
a9612e28-f0c0-4792-8be5-e14b2cd07408
Mukherjee, Somnath
d9278fe6-ec80-45e0-b3ab-137e668787e8

Huggett, Matthew T., Passant, Helen, Hurt, Chris, Pereira, Stephen P., Bridgewater, John and Mukherjee, Somnath (2014) Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom. Tumori, 100 (2), 219-224. (doi:10.1177/030089161410000217).

Record type: Article

Abstract

Aims and background: the ABC-02 trial has defined the standard therapy for patients with advanced biliary tract cancer (ABC); however, outcome in an unselected patient population in the UK has not been described. We aimed to investigate the outcome of a series of patients with ABC from two large UK cancer networks.

Methods and study design: we retrospectively reviewed all cases of ABC presenting to two UK cancer networks over a nine-year period. Overall survival (OS) and factors influencing OS were assessed.

Results: four hundred and two patients were available for analysis. The median OS was 6.2 months. On univariate analysis, age ≥70 years (P = 0.047), advanced disease stage (P <0.001), gall bladder primary (P = 0.033), poor performance status (P <0.001) and lack of chemotherapy (P <0.001) were associated with worse outcome. Survival was superior in the 36.4% of patients who received palliative chemotherapy (12.5 vs 4.3 months; P <0.001). On multivariate analysis of patients who had chemotherapy, those who did not receive fluoropyrimidine-based regimens (HR = 5.12; P = 0.022) or gemcitabine-based regimens (HR = 5.01; P = 0.021) had a higher mortality, whereas the effect of platinum-containing regimens was of borderline significance (HR = 2.23; P = 0.086). Sites, age, and multi-agent regimens were not significant.

Conclusions: this is one of the largest retrospective studies reporting outcome of palliative chemotherapy for ABC. It confirms the benefit of palliative chemotherapy in an unselected group of patients. Fluoropyrimidine-based regimens appear to be as effective as gemcitabine-based treatments.

This record has no associated files available for download.

More information

Accepted/In Press date: 10 September 2013
e-pub ahead of print date: 29 January 2014

Identifiers

Local EPrints ID: 488261
URI: http://eprints.soton.ac.uk/id/eprint/488261
ISSN: 0300-8916
PURE UUID: e1686cc8-d848-4a2a-8b3e-39bf7444fad6
ORCID for Chris Hurt: ORCID iD orcid.org/0000-0003-1206-8355

Catalogue record

Date deposited: 19 Mar 2024 17:46
Last modified: 23 Mar 2024 03:13

Export record

Altmetrics

Contributors

Author: Matthew T. Huggett
Author: Helen Passant
Author: Chris Hurt ORCID iD
Author: Stephen P. Pereira
Author: John Bridgewater
Author: Somnath Mukherjee

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×